China's NMPA Gatekeeper: The In-China Domestic Agent Explained

This episode demystifies the mandatory role of the In-China Domestic Agent for foreign medical device manufacturers entering the Chinese market. We explore the legal basis under State Council Order 739, effective June 1, 2021, and detail the agent's critical responsibilities in registration, NMPA communication, post-market surveillance, adverse event reporting, and recall management. Learn why selecting the right agent is a vital strategic decision for ensuring long-term regulatory compliance in China. Key Questions: • What is an In-China Domestic Agent and why is it mandatory for medical device manufacturers? • Which key regulation defines the responsibilities of the agent? • How does the agent facilitate initial product registration and filing with the NMPA? • What are the agent's crucial duties regarding post-market surveillance and adverse event reporting? • Who is responsible for coordinating a product recall in China? • How does the agent act as a communication bridge between the manufacturer and Chinese authorities? • Why is the choice of an agent more than just an administrative step? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.